In an interview to CNBC-TV18, Nikhil Nanda, MD of JHS Svendgaard Laboratories gave his outlook for the year.
The company is now focusing on shifting focus from being pure contract manufacturers to owing brands, says Nikhil Nanda, MD of the company.
Nikhil Nanda, MD, JHS Svendgaard Laboratories says the dilution of the company will be such that the promoter stake will rise to 45 percent from the current 37 percent.
In an interview to CNBC-TV18, Nikhil Nanda, managing director of JHS Svendgaard Laboratories says, the company has taken price hike to protect its margins.
JHS Svendgaard rallied as the company planned to resume export of tooth brushes. It had also closed a deal with Amway to sell the tooth brushes. The company hiked prices by the end of this quarter on account of increase in raw material based on the input material that it uses for each of the customers.
Nikhil Nanda, managing director, JHS Svendgaard in an interview to CNBC-TV18 said, the company's margins are under tremendous pressure because of prices of most of its raw materials are increasing on a regular basis.
JHS Svendgaard Laboratories has decided to do a preferential allotment of 25,00,000 equity shares to Tano Mauritius India FVCI at a price of Rs. 97.75. Tano Mauritius will hold about 14.8% in the company, Nanda says.
Nikhil Nanda, MD of JHS Svendgaard, in an interview with CNBC-TV18’s Reema Tendulkar and Ekta Batra, spoke about the recent happenings in the company and the future ahead.